INSUBCONTINENT EXCLUSIVE:
Strides Pharma Science shares were outperforming the Sensex.Strides Pharma Science shares surged as much as 5 per cent to hit an intraday
high of Rs 431.15 after it got approval from US drug regulator - US Food and Drug Administration (USFDA) - for Butalbital, Acetaminophen,
"Strides Pharma Science's wholly owned subsidiary Strides Pharma Global Pte
Singapore, has received approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, 50 mg/325 mg/40 mg/30 mg from the
United States Food - Drug Administration (USFDA)," Strides Pharma Science said in a stock exchange filing.The product is a generic version
2020 data, the US market for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, 50 mg/325 mg/40 mg/30 mg is approximately
The product will be marketed by Strides Pharma in the US market," Strides Pharma added."Butalbital, Acetaminophen, Caffeine, and Codeine
Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache," Strides Pharma said.As
of 11:52 am, Strides Pharma Science shares traded 2.66 per cent higher at Rs 422.30, outperforming the Sensex which was up 0.67 per cent.
